Clinical Trial Update: Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study of CB-839 (telaglenastat), a glutaminase inhibitor, in hematological tumors including non-H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma
• T-cell Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• CB-839 (telaglenastat) (telaglenastat)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma | Phase 1 | Status: COMPLETED